MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Results from peopleCompletedDid not show the hoped-for effect

Phase 2

PIPE-307: the Phase 2 VISTA study did not show the hoped-for benefit

Worth knowing

In relapsing-remitting MS, PIPE-307 had acceptable safety and tolerability, but it did not reach the study's main or secondary measures of benefit.

What this means for people with MS

One of the most discussed drugs designed specifically to repair myelin did not show benefit in Phase 2. It is uncertain whether development for MS will continue.

What kind of evidence exists?
Initial public results from the company
How reliable is this source?
Strong for the initial result • official company filing, not a full paper reviewed by independent scientists

Related study or programme: PIPE-307 / VISTA →

Official company filingRead the source ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Read the update →Peer-reviewed paper
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Read the update →University / investigator